Article Text

Download PDFPDF

Efficacy and safety of acupuncture for chemotherapy-induced leucopoenia: protocol for a systematic review
  1. Jiayun Nian1,2,
  2. Xu Sun1,
  3. Jiao Guo1,2,
  4. Chen Yan1,2,
  5. Xiaomin Wang1,
  6. Guowang Yang1,
  7. Lin Yang1,
  8. Mingwei Yu1,
  9. Ganlin Zhang1
  1. 1Oncology Department, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, China
  2. 2School of Graduates, Beijing University of Chinese Medicine, Beijing, China
  1. Correspondence to Professor Xiaomin Wang; wangxiaomin_bhtcm{at}126.com

Abstract

Introduction Many cancer patients experience leucopoenia during chemotherapy. Granulocyte- colony-stimulating factor (G-CSF) is used to treat chemotherapy-induced leucopoenia (CIL) but has various limitations. Clinical trials have indicated that acupuncture may prevent bone marrow suppression and increase leucocyte counts after chemotherapy. The objective of this review is to assess the efficacy and safety of acupuncture for treating CIL.

Methods and analysis This systematic review will electronically search the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library, Medline, EMBASE, the China National Knowledge Infrastructure Database (CNKI), the Chinese Biomedical Literature Database (CBM), the Chinese Scientific Journal Database (VIP Database) and the Wanfang database from their inception to 1 January 2016. Other sources will also be searched including potential grey literature, conference proceedings and the reference lists of identified publications and existing systematic reviews. Two reviewers will independently search the databases, perform data extraction and assess the quality of studies. Data will be synthesised by either the fixed-effects or the random-effects model according to a heterogeneity test. White blood cell counts will be assessed as the primary outcome. Adverse effects, incidence of leucopoenia, quality of life and physical condition will be evaluated as secondary outcomes. RevMan V.5.3 will be employed for data analysis. The results will be expressed as risk ratios for dichotomous data and mean differences for continuous data.

Ethics and dissemination The protocol does not need ethics approval because individuals cannot be identified. The review will be reported in a peer-reviewed publication or at a relevant conference.

Trial registration number CRD42015027594.

  • CHEMOTHERAPY
  • ONCOLOGY
  • HAEMATOLOGY

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.